Earnings Call · Q2 FY2023·2023-08-02

Q2 23EPS +100.00%*·Rev n/aQ1 23EPS -28.57%·Rev n/aQ4 22EPS -8.33%·Rev n/aQ3 22EPS +15.00%·Rev n/a⚠ consensus missing

ACADIA PHARMACEUTICALS INC ACAD

Jessica Tieszen — Investor Relations or Communications (host of the call)

Steve Davis — Chief Executive Officer

Brendan Teehan — Chief Operating Officer

Doug Williamson — Chief Medical Officer

Mark Schneyer — Chief Financial Officer

−3.3%1d on move date−3.5% vs SPY3d−6.6%5d−10.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ACAD calls or request research access.

More ACAD calls Browse calls Request research access